Načítá se...
Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL
VGX-3100 is an investigational DNA-based immunotherapy being developed as an alternative to surgery and ablation for cervical High-Grade Squamous Intraepithelial Lesion (HSIL) with the aim of preserving reproductive health while treating precancerous disease. Response durability up to 1.5 y followin...
Uloženo v:
| Vydáno v: | Hum Vaccin Immunother |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Taylor & Francis
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8078703/ https://ncbi.nlm.nih.gov/pubmed/33175656 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2020.1823778 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|